Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

BNT162b2 Booster Dose Elicits a Robust Antibody Response in Subjects with Abdominal Obesity and Previous SARS-CoV-2 Infection

Version 1 : Received: 1 November 2023 / Approved: 2 November 2023 / Online: 2 November 2023 (14:42:21 CET)

A peer-reviewed article of this Preprint also exists.

Malavazos, A.E.; Dubini, C.; Milani, V.; Boveri, S.; Meregalli, C.; Bertolini, C.; Buscemi, C.; Cardani, R.; Renna, L.V.; Trevisan, M.B.; Scravaglieri, V.; Cuppone, M.T.; Menicanti, L.; Costa, E.; Ambrogi, F.; Ruocco, C.; Carruba, M.; Iacobellis, G.; Nisoli, E.; Corsi Romanelli, M.M. BNT162b2 Booster Dose Elicits a Robust Antibody Response in Subjects with Abdominal Obesity and Previous SARS-CoV-2 Infection. Vaccines 2023, 11, 1796. Malavazos, A.E.; Dubini, C.; Milani, V.; Boveri, S.; Meregalli, C.; Bertolini, C.; Buscemi, C.; Cardani, R.; Renna, L.V.; Trevisan, M.B.; Scravaglieri, V.; Cuppone, M.T.; Menicanti, L.; Costa, E.; Ambrogi, F.; Ruocco, C.; Carruba, M.; Iacobellis, G.; Nisoli, E.; Corsi Romanelli, M.M. BNT162b2 Booster Dose Elicits a Robust Antibody Response in Subjects with Abdominal Obesity and Previous SARS-CoV-2 Infection. Vaccines 2023, 11, 1796.

Abstract

Little is known about the long-term durability of the induced immune response in subjects af-fected by obesity, particularly in those with an abdominal distribution of adipose tissue. We evaluated SARS-CoV-2-specific antibody response after BNT162b2 vaccine booster dose, com-paring individuals with abdominal obesity (AO) with those without, discerning between indi-viduals previously infected or not. IgG-TrimericS were measured in 511 subjects at baseline, 21 days after vaccine dose-1 and at one, three, six and nine months after dose-2 and at one and three months after booster dose. Nucleocapsid antibodies were assessed at baseline and at the end of the study to detect SARS-CoV-2 infection. To evaluate the three-months difference in absolute variation of IgG-TrmicericS levels from booster dose we used multivariable linear regression that showed interaction between AO and SARS-CoV-2 infection status (p=0.016). AO is associated with higher absolute IgG-TrimericS variation in prior infected individuals, regardless of possi-ble confounders and IgG-TrimericS levels at booster dose (p=0.0125). No interaction was evinced using BMI in the same regression model (p=0.418). The robust response in the development of antibodies after booster dose, observed in people with OA and previous infection, may support the recommendations to undergo the booster dose also in this population group.

Keywords

Abdominal obesity, obesity, BMI, BNT162b2 mRNA vaccine, antibody response, IgG-TrimericS, booster dose, COVID-19

Subject

Public Health and Healthcare, Public Health and Health Services

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.